FATE - フェイト・セラピュ―ティクス (Fate Therapeutics Inc.) フェイト・セラピュ―ティクス

 FATEのチャート


 FATEの企業情報

symbol FATE
会社名 Fate Therapeutics Inc (フェイト・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フェイト・セラピューティクス(Fate Therapeutics Inc)は臨床段階のバイオ医薬品会社である。同社はがんおよび免疫障害のためのプログラム細胞免疫療法の開発に従事する。同社の細胞治療パイプラインは改変誘導多能性細胞による癌免疫療法を含む免疫腫瘍学プログラム、造血細胞移植を受けている患者の免疫系を保護し、自己免疫を抑制するための造血細胞免疫療法を含む免疫調節プログラムを含む。リード臨床プログラムはプログラム免疫調節細胞療法であるProTmuneである。同社は細胞プログラミング手法を利用して、CD34 +細胞、ナチュラルキラー(NK)細胞およびT細胞などの免疫細胞をプログラムする。養子細胞治療プログラムは、治療機能を調節し、免疫細胞のフェイトを導くために適用される同社の体外細胞プログラミングアプローチに基づく。   フェイト・セラピュ―ティクスは、米国のバイオベンチャ―企業。幹細胞関連で先進的な医薬品の創製を目指す。造血幹細胞の移植後の定着を高める作用を持つ幹細胞調整薬「FT 1050」の開発などに注力。なお、人工多能性幹細胞(iPS細胞)の作製にかかわる実験法の特許を所有する。本社は、カリフォルニア州サンディエゴ。   Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
本社所在地 3535 General Atomics Court Suite 200 San Diego CA 92121 USA
代表者氏名 William H. Rastetter ウィリアムH.ラスターセッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-875-1803
設立年月日 39173
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 80人
url www.fatetherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/fate
adr_tso
EBITDA EBITDA(百万ドル) -55.14200
終値(lastsale) 14.96
時価総額(marketcap) 799151067.44
時価総額 時価総額(百万ドル) 888.97060
売上高 売上高(百万ドル) 4.10600
企業価値(EV) 企業価値(EV)(百万ドル) 825.80060
当期純利益 当期純利益(百万ドル) -56.97000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fate Therapeutics Inc revenues remained flat at $2.1M. Net loss increased 71% to $33.8M. Revenues reflect market conditions. Higher net loss reflects Research_Development increase of 81% to $26.6M (expense) Other general_Administrative Expenses increase of 24% to $6.2M (expense) Stock-based Compensation in SGA increase of 75% to $1.2M (expense).

 FATEのテクニカル分析


 FATEのニュース

   Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Buy” by Analysts  2020/10/25 00:44:41 US Banking News
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus recommendation of “Buy” from the seventeen analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has issued a strong buy […]
   Zacks Investment Research Downgrades Fate Therapeutics (NASDAQ:FATE) to Strong Sell  2020/10/24 01:34:41 Daily Political
Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Thursday, Zacks.com reports. They presently have a $37.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential downside of 23.49% from the stock’s […]
   Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Sells $1,467,249.75 in Stock  2020/10/23 05:02:41 Dispatch Tribunal
Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 29,199 shares of the stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $50.25, for a total value of $1,467,249.75. Following the completion of the sale, the general counsel now directly owns 128,717 shares of the […]
   Fate Therapeutics (NASDAQ:FATE) Cut to “Strong Sell” at Zacks Investment Research  2020/10/22 14:35:14 Transcript Daily
Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Thursday, Zacks.com reports. They currently have a $37.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective indicates a potential downside of 20.96% from the stock’s previous […]
   Cindy Tahl Sells 29,199 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) Stock  2020/10/22 08:24:49 Zolmax News
Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 29,199 shares of the business’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $50.25, for a total transaction of $1,467,249.75. Following the completion of the transaction, the general counsel now directly owns 128,717 shares of […]
   Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress  2020/08/05 20:01:00 GlobeNewswire
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with…
   The FLAG Award For Teaching Excellence Awards $25,000 To NYC Public School Teacher Lou Lahana And A $95,000 Grant To His School, PS/MS 188, The Island School  2020/07/29 12:03:00 PR Newswire
NEW YORK, July 29, 2020 /PRNewswire/ -- The FLAG Award for Teaching Excellence (FATE) announces Dr. Lou Lahana as the winner of its inaugural prize, which includes a $25,000 unrestricted cash prize as well as an additional $95,000 to be used for an arts-based initiative at Dr. Lahana's…
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Notable Insider Buys Last Week: Cigna, Fox, Uber And More  2020/06/20 20:08:17 Benzinga Feeds
Insider buying can be an encouraging signal for potential investors. Some insiders took advantage of a secondary offering last week. Two chief executives also have stepped up to the buy window. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty. Insiders continued to add shares despite overall market volatility and economic uncertainty. The following are some of the most noteworthy insider purchases reported in the past week. A director at Axis Capital Holdings Limited (NYSE: AXS ) indirectly bought less than 1.35 million shares of this Bermuda-based company at between $38.77 and $42.50 each. That totaled around $55.67 million, and it almost doubled the director's stake. A Fate Therapeutics Inc (NASDAQ: FATE ) director indirectly picked up more than 1.41 million shares of this biopharmaceutical company for $28.31 each.
   Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)  2020/06/15 17:44:29 Yahoo Finance
In this article we will check out the progression of hedge fund sentiment towards Fate Therapeutics Inc (NASDAQ:FATE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on
   Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress  2020/08/05 20:01:00 GlobeNewswire
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with…
   The FLAG Award For Teaching Excellence Awards $25,000 To NYC Public School Teacher Lou Lahana And A $95,000 Grant To His School, PS/MS 188, The Island School  2020/07/29 12:03:00 PR Newswire
NEW YORK, July 29, 2020 /PRNewswire/ -- The FLAG Award for Teaching Excellence (FATE) announces Dr. Lou Lahana as the winner of its inaugural prize, which includes a $25,000 unrestricted cash prize as well as an additional $95,000 to be used for an arts-based initiative at Dr. Lahana's…
   The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy  2020/07/08 11:31:40 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) ( announced initiation of a Phase 1 study of a potential coronavirus treatment) Crispr Therapeutics AG (NASDAQ: CRSP ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Immunomedics, Inc.
   Notable Insider Buys Last Week: Cigna, Fox, Uber And More  2020/06/20 20:08:17 Benzinga Feeds
Insider buying can be an encouraging signal for potential investors. Some insiders took advantage of a secondary offering last week. Two chief executives also have stepped up to the buy window. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty. Insiders continued to add shares despite overall market volatility and economic uncertainty. The following are some of the most noteworthy insider purchases reported in the past week. A director at Axis Capital Holdings Limited (NYSE: AXS ) indirectly bought less than 1.35 million shares of this Bermuda-based company at between $38.77 and $42.50 each. That totaled around $55.67 million, and it almost doubled the director's stake. A Fate Therapeutics Inc (NASDAQ: FATE ) director indirectly picked up more than 1.41 million shares of this biopharmaceutical company for $28.31 each.
   Hedge Funds Keep Buying Fate Therapeutics Inc (FATE)  2020/06/15 17:44:29 Yahoo Finance
In this article we will check out the progression of hedge fund sentiment towards Fate Therapeutics Inc (NASDAQ:FATE) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フェイト・セラピュ―ティクス FATE Fate Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)